trending Market Intelligence /marketintelligence/en/news-insights/trending/RscBPXh9-esbVJ7vqByh3Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BeiGene acquires license from EUSA Pharma to commercialize 2 drugs in Asia

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


BeiGene acquires license from EUSA Pharma to commercialize 2 drugs in Asia

BeiGene Ltd. agreed to acquire an exclusive license from EUSA Pharma Inc. to develop and commercialize Sylvant and Qarziba in parts of Asia.

Beijing-based BeiGene agreed to make an undisclosed upfront payment to EUSA Pharma for the license, which covers mainland China, as well as Hong Kong, Macau and Taiwan. BeiGene will be responsible for all clinical development and regulatory submissions in the respective regions.

EUSA will be eligible to receive milestone payments for up to $160 million and royalties on future product sales.

Sylvant, or siltuximab, is approved in multiple countries to treat a rare, potentially life-threatening disorder called idiopathic multicentric Castleman's disease. Qarziba, or dinutuximab beta, is approved in the EU to treat high-risk neuroblastoma, a rare form of cancer that starts in special nerve cells that are left behind from a baby's development in the womb. It affects children and young people.

China's National Medical Products Administration has listed both the drugs for fast-track approval.

Jefferies International Ltd. was the exclusive advisor to EUSA on the transaction.